Biotech

Applied DNA earns new SigNature patent, more T’d up

By GREGORY ZELLER // Applied DNA Sciences has added two new U.S. patents to its impressive collection – at least, a new patent-and-a-half. The Stony Brook-based supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist announced this week the arrival of U.S. Patent No. 9,790,538, covering “Alkaline Activation for Immobilization of DNA Taggants” – essentially, protecting the core technology powering Applied DNA’s SigNature T molecular tags. The biotech also announced a Notice of Allowance on U.S. Patent Application…

Read More

Applied DNA enlists with Army’s bio-warfare defenders

By GREGORY ZELLER // Applied DNA Sciences is in the Army now. Already under U.S. Department of Defense contract on a number of different projects, the Stony Brook-based biotech has entered into a new Cooperative Research and Development Agreement with U.S. Army Research, Development and Engineering Command’s Edgewood Chemical Biological Center. Best known as a developer and distributor of in-house botanical-DNA-based security and authentication protocols, Applied DNA is lending its expertise in a slightly different…


Global nod marks major milestone for Applied DNA

By GREGORY ZELLER // An esteemed international certification organization has stamped a ginning company tracking its cotton supplies with the help of Applied DNA Sciences. The Global Organic Textile Standard certification is another feather in the cap of the Stony Brook biotech, which has long banked on cotton and other textile-focused industries as a business-development cornerstone. The certification was awarded to Woolam Gin of Texas, an Applied DNA “ginning partner,” by Netherlands-based Control Union Certifications,…


ALZ: Genetic variants can run, but they can’t hide

The Feinstein Institute for Medical Research is targeting genetic risk factors behind Alzheimer’s disease, the first of many steps toward new potential treatments. Feinstein Institute assistant professor Yun Freudenberg-Hua has been awarded a five-year, $600,000 grant by the National Institutes of Health’s National Institute on Aging, supporting her mission to better understand the genetic causes of a disease that inflicts an estimated 5.5 million Americans. Ultimately, the doctor and her staff hope to develop new…


NYIT: ‘Lethal interactions’ could stop tough cancers

New York Institute of Technology researchers may have found a way to stop cancerous tumors from spreading through the central nervous system. And for some patients suffering from the worst cancers – and the traditionally awful side effects of conventional chemotherapy – help may be on the way. A July issue of the journal Proceedings of the National Academy of Sciences chronicles the work of associate professor Dong Zhang and his team at NYIT’s College…


For Applied DNA, real growth in fertilizer

By GREGORY ZELLER // Applied DNA Sciences, the Stony Brook biotech, has spent 2017 aggressively introducing its DNA-based supply chain, anti-counterfeiting and anti-theft technologies to new industries and markets – and now adds fertilizer, a critical commodity for global farmers, to its growing list. Less than a month after applying its CertainT authentication platform to plastics – specifically, thermoplastic polymer resin – through a multi-year licensing deal with Indian global textile manufacturer GHCL Ltd., Applied…


Concussion-focused Scythian sets market debut

By GREGORY ZELLER // Scythian Biosciences Corp. is going public. The New York City/Toronto-based biotech, led by Great Neck investment banker Jonathan Gilbert on its quest to develop the world’s first pharmaceutical treatment for concussions, will begin trading Aug. 8 on the TSX Venture Exchange, one of Canada’s major stock markets. Projected to open at $8 (Canadian) per share, Scythian Biosciences (ticker symbol “SCYB”) will float upwards of 2.5 million shares – about half of…